Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: This is from the other board and is very important, IMHO.

I'll tell you whats going on, the same thing that's gone on since I've owned the stock. When we start seeing red a few days before the release it means the numbers are sub-par or lower. It has been this way every time. Investors shouldn't be expecting something out of the ordinary. I think Lambert's projections are within reason. Anyone expecting more is setting themselves up for disappointment. I hear what everyone is saying about the Crossflo financial terms but, I don't think it was a strategic move. I think it was done out of necessity because of PTSC's weak capital position. When I say that I'm referring specifically to the lack of revenue that is being generated by the MMP. Does anyone here really believe that Crossflo was a great steal bought on the cheap? Considering they sold for $2+ million cash and shares in an OTC company I believe that tells you the financial shape they were in. I'm not saying it isn't a good deal just being realistic with my expectations on the near term impact to PTSC's bottom line. I believe we are in the very early stages of the attempted "Umbrella Strategy" therefore it is reasonable to assume a secondary revenue stream is still a ways off. IMO.

Share
New Message
Please login to post a reply